About Capio Biosciences
Founded in 2015 by cofounders Seungpyo Hong PhD (UW, Madison WI) and Andrew Wang MD (UNC, Chapel Hill NC), Capio Biosciences is a biotech start-up focused on delivering high-value oncology diagnostics that can help inform patient care decisions and improve outcomes. At Capio Biosciences we are currently developing an advanced platform called CapioCyte™ for the capture of circulating tumor cells (CTCs) from whole blood. By utilizing a combination of biomimetic cell rolling and dendrimer-mediated multivalent cell capture, CapioCyte delivers significantly greater capture sensitivity than other platforms currently available. It is also able to provide enriched CTCs for post capture molecular analysis such as FISH, RNA-Seq and NGS. CapioCyte is therefore an excellent tool for today’s cancer research needs, and potentially for clinical patient management in the future.
Our Vision: To be the world’s leading liquid biopsy company providing valuable clinical information to improve patient outcomes.
Are you looking for your next challenge? We seek accomplished, passionate, creative individuals to join a liked minded team in a supportive fast growing start up environment. Join us at Capiobiosciences where intelligent highly committed individuals are given the freedom, ownership, and resources to make an impact on cancer management.
Interested? We would love to hear from you.
Contact us at: email@example.com